Editorial Commentary: When should the patient with an inherited cardiac disease have an ICD?

Publikation: Bidrag til tidsskriftKommentar/debatForskningfagfællebedømt

Standard

Editorial Commentary : When should the patient with an inherited cardiac disease have an ICD? / Winkel, Bo Gregers; Tfelt-Hansen, Jacob.

I: Trends in Cardiovascular Medicine, Bind 30, Nr. 7, 10.2020, s. 422-423.

Publikation: Bidrag til tidsskriftKommentar/debatForskningfagfællebedømt

Harvard

Winkel, BG & Tfelt-Hansen, J 2020, 'Editorial Commentary: When should the patient with an inherited cardiac disease have an ICD?', Trends in Cardiovascular Medicine, bind 30, nr. 7, s. 422-423. https://doi.org/10.1016/j.tcm.2019.11.004

APA

Winkel, B. G., & Tfelt-Hansen, J. (2020). Editorial Commentary: When should the patient with an inherited cardiac disease have an ICD? Trends in Cardiovascular Medicine, 30(7), 422-423. https://doi.org/10.1016/j.tcm.2019.11.004

Vancouver

Winkel BG, Tfelt-Hansen J. Editorial Commentary: When should the patient with an inherited cardiac disease have an ICD? Trends in Cardiovascular Medicine. 2020 okt.;30(7):422-423. https://doi.org/10.1016/j.tcm.2019.11.004

Author

Winkel, Bo Gregers ; Tfelt-Hansen, Jacob. / Editorial Commentary : When should the patient with an inherited cardiac disease have an ICD?. I: Trends in Cardiovascular Medicine. 2020 ; Bind 30, Nr. 7. s. 422-423.

Bibtex

@article{6519697adbf84722b874e5c351dc913c,
title = "Editorial Commentary: When should the patient with an inherited cardiac disease have an ICD?",
abstract = "The implantable cardioverter defibrillator (ICD) is often considered a routine intervention for an inherited heart rhythm disorder (IHRD) despite there being little to no randomized data for non-ischemic indications. Furthermore, existing IHRD studies often do not report adverse ICD outcomes, and observational data increasingly show that complications are under-recognized. Only recently have tools emerged to address the rational use of ICDs for specific forms of IHRD, although the acceptable risk of device complications remains unestablished. Here, we summarize the evidence of ICD benefit and harm in IHRD, highlight current knowledge gaps, and propose alternative and adjunctive options to the transvenous ICD.",
author = "Winkel, {Bo Gregers} and Jacob Tfelt-Hansen",
note = "Copyright {\textcopyright} 2019 Elsevier Inc. All rights reserved.",
year = "2020",
month = oct,
doi = "10.1016/j.tcm.2019.11.004",
language = "English",
volume = "30",
pages = "422--423",
journal = "Trends in Cardiovascular Medicine",
issn = "1050-1738",
publisher = "Elsevier",
number = "7",

}

RIS

TY - JOUR

T1 - Editorial Commentary

T2 - When should the patient with an inherited cardiac disease have an ICD?

AU - Winkel, Bo Gregers

AU - Tfelt-Hansen, Jacob

N1 - Copyright © 2019 Elsevier Inc. All rights reserved.

PY - 2020/10

Y1 - 2020/10

N2 - The implantable cardioverter defibrillator (ICD) is often considered a routine intervention for an inherited heart rhythm disorder (IHRD) despite there being little to no randomized data for non-ischemic indications. Furthermore, existing IHRD studies often do not report adverse ICD outcomes, and observational data increasingly show that complications are under-recognized. Only recently have tools emerged to address the rational use of ICDs for specific forms of IHRD, although the acceptable risk of device complications remains unestablished. Here, we summarize the evidence of ICD benefit and harm in IHRD, highlight current knowledge gaps, and propose alternative and adjunctive options to the transvenous ICD.

AB - The implantable cardioverter defibrillator (ICD) is often considered a routine intervention for an inherited heart rhythm disorder (IHRD) despite there being little to no randomized data for non-ischemic indications. Furthermore, existing IHRD studies often do not report adverse ICD outcomes, and observational data increasingly show that complications are under-recognized. Only recently have tools emerged to address the rational use of ICDs for specific forms of IHRD, although the acceptable risk of device complications remains unestablished. Here, we summarize the evidence of ICD benefit and harm in IHRD, highlight current knowledge gaps, and propose alternative and adjunctive options to the transvenous ICD.

U2 - 10.1016/j.tcm.2019.11.004

DO - 10.1016/j.tcm.2019.11.004

M3 - Comment/debate

C2 - 31812250

VL - 30

SP - 422

EP - 423

JO - Trends in Cardiovascular Medicine

JF - Trends in Cardiovascular Medicine

SN - 1050-1738

IS - 7

ER -

ID: 232013113